This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186–189 (2003).
Shaw-Stiffel, T. & Kim, W. R. Global epidemiology and burden of hepatitis C. Microbes Infect. 4, 1219–1225 (2002).
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Smith, R. Hepatitis C virus therapies. Nat Rev Drug Discov 5, 715–716 (2006). https://doi.org/10.1038/nrd2134
Issue Date:
DOI: https://doi.org/10.1038/nrd2134
This article is cited by
-
GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo
Acta Pharmacologica Sinica (2018)
-
Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors
Journal of Computer-Aided Molecular Design (2008)